|
gptkbp:instanceOf
|
Biotechnology company
|
|
gptkbp:acquisition
|
Zymeworks 2021
|
|
gptkbp:awards
|
Top Employer (2021)
Best Workplace (2020)
Innovative_Company_(2019)
|
|
gptkbp:CEO
|
gptkb:Ali_Tehrani
|
|
gptkbp:clinicalTrials
|
Phase 1
Phase 2
Phase 3
|
|
gptkbp:collaborations
|
gptkb:University_of_British_Columbia
gptkb:Simon_Fraser_University
gptkb:University_of_Alberta
|
|
gptkbp:communityPartnerships
|
gptkb:Canadian_Institutes_of_Health_Research
gptkb:National_Cancer_Institute
gptkb:National_Institutes_of_Health
|
|
gptkbp:employees
|
over 200
|
|
gptkbp:focus
|
therapeutics
|
|
gptkbp:founded
|
2003
|
|
gptkbp:founder
|
gptkb:Ali_Tehrani
|
|
gptkbp:headquarters
|
gptkb:Vancouver,_Canada
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zymeworks Inc.
|
|
gptkbp:investmentFocus
|
Institutional Investors
Public Investors
Venture_Capital
|
|
gptkbp:location
|
gptkb:Asia
gptkb:North_America
Europe
|
|
gptkbp:netIncome
|
-$50 million (2020)
|
|
gptkbp:partnerships
|
gptkb:Bristol-Myers_Squibb
gptkb:Merck_&_Co.
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:products
|
Zymeworks_Zymeworks_2021
|
|
gptkbp:researchFocus
|
autoimmune diseases
infectious diseases
cancer therapies
|
|
gptkbp:revenue
|
$30 million (2020)
|
|
gptkbp:stockSymbol
|
ZYME
|
|
gptkbp:subsidiary
|
Zymeworks USA, Inc.
Zymeworks_Asia_Ltd.
Zymeworks_Europe_Ltd.
|
|
gptkbp:technology
|
Zymeworks 2021 platform
Zymbody
Zymeworks'_proprietary_platform
|
|
gptkbp:tradedOn
|
gptkb:TSX
gptkb:NYSE
|
|
gptkbp:website
|
www.zymeworks.com
|